ADMA Biologics, Inc. Faces Class Action Lawsuit Amid Allegations of Fraudulent Practices

On July 28, 2026, The Gross Law Firm announced a critical notice for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA), regarding a class action lawsuit initiated due to allegations of significantly misleading statements and undisclosed practices. Investors who purchased shares in ADMA Biologics during the specified class period from August 9, 2024, to March 25, 2026, are encouraged to contact the law firm for potential involvement in the recovery process.

Context of the Allegations

The allegations set forth in this lawsuit suggest that during the class period, ADMA Biologics made several assertions that were misleading or false. The lawsuit accuses the company of several key issues:

1. Undisclosed Related Party Transactions: The defendants are alleged to have participated in transactions with related parties that were not disclosed to shareholders, raising flags about transparency and corporate governance.
2. Channel Stuffing Practices: The complaint asserts that ADMA Biologics engaged in channel stuffing to artificially inflate revenue figures, misleading investors about the company's actual financial health.
3. Inadequate Internal Controls: The suit highlights a lack of effective internal controls that should have ensured accurate reporting and compliance with financial regulations.
4. Misleading Statements: Due to the first three issues, the defendants’ claims regarding ADMA Biologics' business operations and future prospects were deemed materially false and misleading throughout the specified timeframe.

Important Deadlines and Registration

Shareholders are urged not to delay in registering for this class action, as the deadline for lead plaintiff applications is set for August 10, 2026. By registering, shareholders gain access to portfolio monitoring software that will supply updates on the case as it progresses. It is important to note that registering as a shareholder does not require anyone to participate as a lead plaintiff, nor does it incur any costs or obligations for the investor.

Why Choose The Gross Law Firm?

The Gross Law Firm is a recognized entity in handling class action lawsuits, with a commitment to safeguarding the rights of investors who may have faced losses due to deceptive business practices. Their extensive experience in navigating complex legal landscapes aims to ensure that companies like ADMA Biologics adhere to ethical business conduct and accountability to their shareholders.

Their primary focus is on recovering damages for individuals who have experienced financial losses stemming from false information or misleading omissions by the companies they invest in. This commitment to corporate citizenship is a cornerstone of their legal approach, as they challenge malpractices that compromise shareholder interests.

Contact Information for Interested Shareholders

Interested shareholders can initiate their registration process by following the guidelines available on the Gross Law Firm's website. Here is the link to contact them: Register Here.

Final Thoughts

As this lawsuit unfolds, its outcomes could have significant implications for ADMA Biologics and its investors. Investors must stay informed and proactive to protect their rights and potential recoveries. The announcement serves as a reminder of the importance of transparency and ethical conduct in corporate governance, vital for maintaining investor confidence in the market.